A Phase IB /II, Multicenter, Open-Label Study of Safety, Tolerability and Efficacy of SHR-A2102 for Injection With or Without Antitumor Therapy in Subjects With Advanced Solid Tumors
Latest Information Update: 03 Jan 2025
At a glance
- Drugs SHR A2102 (Primary) ; Adebrelimab
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Shanghai Hengrui Pharmaceutical
Most Recent Events
- 31 Dec 2024 Status changed from not yet recruiting to recruiting.
- 21 May 2024 New trial record